HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech Programs In U.S., EU, Move Regs Closer To Global Model

This article was originally published in The Rose Sheet

Executive Summary

The regulation of nanotechnology continues moving towards a harmonized model as agencies on both sides of the Atlantic announce new funds and collaborations towards safety assessments.

You may also be interested in...



Korea, Russia And Singapore Establish Asia Nanotechnology Fund

SEOUL - Korea, Russia and Singapore have established the Asia Nanotechnology Fund, which will make investments in nanotechnology-related projects in Russia and Asia

FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron

In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.

FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron

In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel